DANAHER CORP /DE/

DANAHER CORP /DE/ (DHR) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The Toll-Bridge Economics: Danaher has successfully positioned itself in the middle of a massive global industry—scientific research and diagnostics. Once a lab adopts their equipment and validates the protocols, the cost of switching is not just financial; it is a regulatory and operational nightmare. This is the definition of a "moat."
• Razor-and-Blade Compounding: The initial equipment sale is simply the entry fee. The true value lies in the $24.6B revenue stream that is dominated by high-margin, recurring consumables. It is a business that essentially taxes the progress of medical science.
• Cash Flow Integrity: The quality of earnings is excellent. When you see FCF of $5.3B outpacing NI of $3.6B, you know you are looking at a business that collects hard cash, not accounting fiction. That is a hallmark of a high-quality franchise.
• The Ideal Price: If the market ever stops pricing this as a "growth" stock and starts pricing it as the stable, cash-generative utility it is, the opportunity would be compelling. We want the toll bridge, but only when we can buy the toll booth at a sensible price.

🐻 The Bear Case (Charlie inverts)

Munger’s Rule: “Show me where I'll die and I won't go there.”

• The Acquisition Treadmill: Danaher has become addicted to "bolt-on" acquisitions like Abcam to mask internal stagnation. When a company with such a formidable moat sees its ROE crash from 11.1% to 6.9%, it tells you one thing: they are running out of good ideas. They are essentially buying growth rather than creating it.
• The Spin-off Shell Game: The collapse of revenue from $16.9B to $4.2B (via spin-offs) proves that this company is more about financial engineering than sustainable business evolution. Eventually, you run out of parts to spin off and companies to acquire. When the M&A engine stalls, the stock will crater because there is no underlying organic growth engine to pick up the slack.
• Capital Allocation Myopia: Reinvesting at a 6.9% return is a disaster. It is a slow-motion destruction of shareholder value. If management keeps pouring money into low-return acquisitions, they are effectively turning capital into ash. We don't invest in businesses that destroy value with every dollar they reinvest.

💰 Valuation & Margin of Safety

Our DCF model reflects a business that is growing, but struggling to convert capital into high returns.

• Intrinsic value estimate: $125.10 per share
• 25% margin of safety entry: $93.83
• 50% margin of safety entry: $62.55

Assessment: The company is currently significantly expensive. The market is paying a premium for the "Danaher name," ignoring the glaring trend of deteriorating returns on capital and the reliance on continuous, high-cost acquisitions to keep the top line moving.

Verdict: PASS

We are passing on Danaher because the current market price reflects a premium that the company’s degrading returns on capital simply do not justify. While the underlying "razor-and-blade" franchise remains stable, management's obsession with acquisition-fueled growth at the expense of shareholder value is a path to permanent capital impairment. We will keep them on the watch list, but only at a price that provides a massive margin of safety for their capital allocation errors.